This metabolic pathway is nonexistent in the healthy body, but becomes important after peripheral L-DOPA administration in patients with Parkinson's disease or in the rare cases of patients with AADC enzyme deficiency.
Esta vía metabólica non existe no corpo san, pero faise importante despois da administración periférica de L-DOPA en pacientes con enfermidade de Parkinson ou nos raros casos de pacientes con deficiencia do encima L-aminoácido aromático descarboxilase (AADC).